New COO appointed at X4 Pharmaceuticals
June 13, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
X4 Pharmaceuticals has announced the appointment of John K. Celebi as its new chief operating officer. Celebi will bring over …
Shire gets FDA breakthrough therapy designation for two rare disease drugs
June 13, 2016Manufacturing and Production, Research and Development, Sales and Marketing Breakthrough Therapy Designation, Shire, US FDA, rare disease, rare disease drugs
Ireland headquartered Shire (LSE: SHP) on Monday said the US Food and Drug Administration (FDA) has granted breakthrough therapy designation …
Lilly showcases positive late-stage data in diabetes treatments
June 13, 2016Research and Development, Sales and Marketing diabetes, lilly
Eli Lilly (NYSE: LLY) has presented data on their diabetes drugs in late-stage trials at the 76th American Diabetes Association …
Weekly Movers: Lion Biotech, Adamis, Sarepta…
June 13, 2016Manufacturing and Production, Research and Development, Sales and Marketing Alexion, Biogen, Shares, Stock Markets, Stock Movement, drug trial, sarepta
Drug trial results remained the important theme over the past week with several companies announcing key study results. The trial …
Novo Nordisk presents Tresiba data showing significantly lower hypoglycaemia rates
June 13, 2016Research and Development, Sales and Marketing Novo Nordisk, Tresiba
Novo Nordisk (CPH: NOVO-B) has presented new Phase IIIb data on Tresiba (insulin degludec) at the American Diabetes Association annual …
Google’s DeepMind to apply artificial intelligence technology to NHS in next five years
June 13, 2016Medical Communications, Research and Development, Sales and Marketing DeepMind, NHS, collaboration, google, health tech
Google’s artificial intelligence company DeepMind Technologies wants to apply its machine learning technology to NHS patient data within the next …
Pfizer’s leukaemia drug beats chemotherapy in Phase III trials
June 13, 2016Research and Development, Sales and Marketing Inotuzumab ozogamicin, Pfizer, acute lymphoblastic leukaemia
Pfizer (NYSE: PFE) has announced data from a pivotal Phase III trial for acute lymphoblastic leukaemia (ALL) drug, inotuzumab ozogamicin, …
Shares in Global Blood jump after positive results for trial sickle cell drug
June 13, 2016Research and Development, Sales and Marketing Global Blood Therapeutics, drug trial, sickle cell disease
Global Blood Therapeutics (Nasdaq: GBT) shares jumped to close up over 9% Friday after the company said its trial drug …
EU ombudsman calls for more transparency from AbbVie on Humira
June 10, 2016Medical Communications, Research and Development AbbVie, EMA, EU, Humira, ombudsman
Abbvie continues to withhold details of clinical trials involving the world’s top-selling prescription medicine, Humira (adalimumab), according to the European …
Boehringer Ingelheim names Simone Menne new chief financial officer
June 10, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim
German drugmaker Boehringer Ingelheim has named Simone Menne as its new chief financial officer. The current CFO at Lufthansa will …
New high-risk treatment can halt MS, claim researchers
June 10, 2016Research and Development multiple sclerosis, research
The results of a Phase II clinical trial, published in The Lancet, suggests that a new use of chemotherapy followed …
FDA committee recommends MSD’s c. diff prevention drug
June 10, 2016Medical Communications, Research and Development, Sales and Marketing FDA, MSD, Merck, bezlotoxumab, committee, zinplava
The US Food and Drug Administration’s (FDA) antimicrobial drugs advisory committee has voted by 10 to 5, with one abstention, …
Merck & Co agrees to buy biotech firm Afferent for upfront $500 million in cash
June 10, 2016Medical Communications, Sales and Marketing Afferent Pharmaceuticals, Financial, M&A, MA, Merck & Co
US drugmaker Merck & Co (NYSE: MRK) said it has agreed to buy biotech firm Afferent Pharmaceuticals for an upfront …
Novartis presents strong results in rare blood disorder trials
June 10, 2016Medical Communications, Research and Development Jakavi, Novartis, Revolade, blood disorder
Novartis has released data from two late-stage trials for rare blood disorders, which showed that Javi (ruxolitinib) is superior to …
Janssen says its immunotherapy daratumumab extends progression-free survival in combination study to treat multiple myeloma
June 10, 2016Medical Communications, Research and Development Janssen, Phase III trials, drug trial, immunotherapy, multiple myeloma
Janssen said late-stage combination trials for its immunotherapy daratumumab increased progression-free survival for patients with multiple myeloma. The company said …
Nice says Bayer’s Eylea not recommended as first-line treatment in draft recommendation
June 10, 2016Medical Communications, Research and Development Bayer, Eylea, NICE, recommendation, regulation
The National Institute for Health and Care Excellence (Nice) in a provisional guidance said Bayer’s (ETR: BAYN) Eylea (aflibercept) is …
FDA targets online illegal prescription drugs sellers
June 10, 2016Medical Communications, Sales and Marketing FDA, Ireland, illegal drug sales
The US Food and Drug Administration (FDA), in partnership with an INTERPOL-led global collaborative effort, has announced that it has …
Amgen, Novartis migraine drug meets primary endpoint in Phase II study
June 9, 2016Research and Development AMG 334, Amgen, Novartis, Phase II, chronic, erenumab, migraine
A new treatment for chronic migraine prevention, co-developed by Novartis (NYSE: NVS) and Amgen (NASDAQ: AMGN), showed a statistically significant …
GSK, Janssen RA treatment meets co-primary endpoints in Phase III trial
June 9, 2016Research and Development GSK, Janssen, eular 2016, rheumatoid arthritis, sirukumab
GSK (LSE: GSK) and Janssen, a division of Johnson and Johnson, have announced data from a pivotal Phase III study …
Sandoz biosimilars as safe and efficacious as originators, says early trials data
June 9, 2016Research and Development Enbrel, MabThera, Novartis, Sandoz, biosimilars, etanercept, rituximab
Sandoz, a division of Novartis, has presented data at the Annual European Congress of Rheumatology (EULAR 2016) demonstrating the safety …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
